On Wednesday, the FDA approved Incyte Corporation (NASDAQ:INCY) and Syndax Pharmaceuticals Inc’s (NASDAQ:SNDX) Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody for chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients. “Niktimvo is Incyte’s second approved treatment for chronic GVHD,” said Hervé Hoppenot, CEO, Incyte. Chronic GVHD is a serious condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor). The donated cells initiate an immune response and attack the transplant recipient’s organs. Also Read: Incyte’s ...